SHARE NOW
Phacilitate’s Georgi Makin and Anna Osborne explore the past year’s gene therapy highlights, before considering what’s required to progress the field even further for 2023 and beyond.
The astounding growth and development we have witnessed in the gene therapy industry over the last decade has not altered course in 2022, with the year playing host to several promising successes in this arena.
Enjoying this article? Download the full eBook, here >>
But what impact has this had on gene therapy development, what challenges remain to be overcome, and what solutions are there for gene therapy developers approaching clinical readiness and regulatory approval?
The State of Industry for Gene Therapies in 2022 at a Glance
According to ASCGT’s Q2 2022 ‘Gene, Cell & RNA Therapy Landscape’ quarterly report, there are currently 3,633 advanced therapies in the preclinical to pre-registration pipelines. Of these, 55%, or
1,998, are gene therapies [1]. Comparing the number of gene therapies in the pipeline at the start of 2021 to the beginning of 2022, there had been a 16% increase, with this number continuing to rise [1].
THIS ARTICLE CONTINUES IN THE FULL EBOOK. DOWNLOAD IT HERE >>
This article has been produced in partnership with WuXi Advanced Therapies. 
